Related Experiment Videos
Relation between height and clinical course in Duchenne muscular dystrophy
M Zatz1, D Rapaport, M Vainzof
1Departamento de Biologia, Universidade de São Paulo, Brazil.
American Journal of Medical Genetics
|February 1, 1988
Summary
Smaller boys with Duchenne muscular dystrophy (DMD) experience slower disease progression. This study found that reduced height correlates with better functional ability and motor skills in DMD patients, suggesting growth inhibition may be beneficial.
Area of Science:
- Pediatrics
- Neurology
- Genetics
Background:
- Duchenne muscular dystrophy (DMD) is a progressive genetic disorder characterized by muscle degeneration.
- Understanding factors influencing DMD clinical progression is crucial for developing effective management strategies.
Purpose of the Study:
- To investigate the relationship between patient height and the rate of clinical progression in boys with Duchenne muscular dystrophy.
- To evaluate the potential impact of growth inhibition on DMD progression.
Main Methods:
- Assessed 111 boys with DMD (age 2-23 years), measuring height in 92 patients.
- Evaluated clinical course using the Vignos scale, motor ability assessments, and timed functional tests.
- Measured serum creatine-kinase (CK) and pyruvate-kinase (PK) levels.
Main Results:
- A statistically significant correlation was observed between height (adjusted for age) and clinical course.
- Smaller boys demonstrated a better clinical course, indicated by a positive correlation with the Vignos scale and a negative correlation with motor ability.
- Elevated CK and PK levels were consistent across all patients.
Conclusions:
- Patient height is a significant factor associated with the rate of clinical progression in Duchenne muscular dystrophy.
- These findings support the hypothesis that growth inhibition may be an effective therapeutic approach to slow DMD progression.